Showing results (131-140 of 380) with videos related to
Sort By:
Pageof 38
Haematologica|July 23, 2026
Relapse risk and survival benchmarks for non-transplanted acute myeloid leukemia patients in first complete remissionEitan Kugler, Farhad Ravandi, Alex Bazinet, et al.Oncotarget|February 13, 2016
Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agentsKoichi Takahashi, Keyur Patel, Carlos Bueso-Ramos, et al.American Journal of Hematology|September 2, 2022
Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patientsGautam Borthakur, Farhad Ravandi, Keyur Patel, et al.American Journal of Hematology|July 21, 2018
Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid LeukemiaMaro Ohanian, Guillermo Garcia-Manero, Mark Levis, et al.Frontiers in Oncology|November 16, 2020
Emergence of BCR-ABL1 Fusion in AML Post-FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance - A Case SeriesAhmad S Alotaibi, Musa Yilmaz, Sanam Loghavi, et al.Clinical Lymphoma, Myeloma & Leukemia|January 28, 2014
Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogeneticsAziz Nazha, Hagop M Kantarjian, Vijaya R Bhatt, et al.Blood|December 12, 2019
Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?Stefan O Ciurea, Piyanuch Kongtim, Ankur Varma, et al.Genome Medicine|March 2, 2017
Characterization of oral and gut microbiome temporal variability in hospitalized cancer patientsJessica R Galloway-Peña, Daniel P Smith, Pranoti Sahasrabhojane, et al.Journal of Hematology & Oncology|June 16, 2021
Impact of frontline treatment approach on outcomes of myeloid blast phase CMLKapil Saxena, Elias Jabbour, Ghayas Issa, et al.American Journal of Hematology|July 19, 2020
Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemiaYasmin Abaza, Hagop Kantarjian, Yasmin Alwash, et al.Pageof 38